Deep Lens has extended one of the world’s first digital pathology cloud platforms that for over ten years has allowed pathology groups to collaborate on groundbreaking cancer research across dozens of cancer types.  

Pharmaceutical and biotech companies turn to Deep Lens because the answers require more than just sequence and EMR data, but rely on the anatomy of the disease as well. For the first time ever, use real time pathology data to go "upstream" of the oncologist and identify patients at the time of diagnosis. Find more patients and shorten trial duration. Discover More...